Short Sessions of HRV Biofeedback

Icahn School of Medicine at Mount Sinai127 enrolled

Overview

Remote 5 minute sessions of heart rate variability (HRV) biofeedback will be employed by participants for 5 weeks. Subjects will be followed for a total of 17 weeks. Surveys assessing psychological well being will be completed during the study period. Wearable devices will be worn to monitor HRV response during the study period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

127

Conditions

Resilience

Interventions

HRV BiofeedbackBEHAVIORAL

5 minute daily sessions of HRV biofeedback

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants were recruited from The Mount Sinai Hospital, Morningside Hospital, Mount Sinai West, Mount Sinai Beth Israel, Mount Sinai Queens, New York Eye and Ear Infirmary, and Mount Sinai Brooklyn. * Eligible participants were 18 years of age or greater. * Had an iPhone series 5 or greater. * Had or were willing to wear an Apple Watch 4 or greater. * Potential participants were excluded if they had an underlying chronic disease or used a medication that is known to impact autonomic nervous system function. Exclusion Criteria: * Underlying chronic diseases including but not limited to: * rheumatoid arthritis * systemic lupus erythematosus * inflammatory bowel disease * Use of medications that impact heart rate variability including but not limited to: * beta-blockers (ie. atenolol, carvedilol, metoprolol, Coreg, Tenormin, Normodyne, Trandate) * digoxin * calcium channel blockers (ie. Norvasc, amlodipine, Cardene, nicardipine, Procardia, nifedipine, Cardizem, diltiazem) * regularly used benzodiazepines

Locations (1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Outcomes

Primary Outcomes

Heart Rate Variability

Heart rate variability measured in milliseconds (ms) at 7 weeks compared to baseline. Higher rates indicate increased parasympathetic nervous system activity.

Time frame: Up to Week 7

Secondary Outcomes

Connor-Davidson Resilience Scale (CD-RISC

Resilience: the Connor-Davidson Resilience scale (CD-RISC) quantifies stress coping ability. The CD-RISC is a 25-item self-administered scale. Scoring of the full 25 item scale is based on summing the total of each item, which is scored from 0-4. The full range is therefore from 0 to 100, with higher scores reflecting greater resilience.

Time frame: Up to Week 17

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.